{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:35:30Z","timestamp":1792100130576,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004046","name":"Karen Elise Jensens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01292-y","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T17:36:12Z","timestamp":1746639372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Temporal changes in survival among adult patients with chronic myeloid leukemia in the period 1995\u20132022\u2014a Danish nationwide population-based register study"],"prefix":"10.1038","volume":"15","author":[{"given":"Sofie Solh\u00f8j","family":"J\u00f8nsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie Amalie","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Faartoft","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Futtrup","family":"Maksten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte Rechter","family":"Zenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren Poulsgaard","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0125-1886","authenticated-orcid":false,"given":"Andreja","family":"Dimitrijevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0996-1812","authenticated-orcid":false,"given":"Marianne Tang","family":"Severinsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"1292_CR1","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bj\u00f6rkholm","year":"2011","unstructured":"Bj\u00f6rkholm M, Ohm L, Eloranta S, Derolf \u00c5, Hultcrantz M, Sj\u00f6berg J, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29:2514.","journal-title":"J Clin Oncol"},{"key":"1292_CR2","unstructured":"Glivec | European Medicines Agency (EMA) [Internet]. [cited 2024 Oct 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/glivec."},{"key":"1292_CR3","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"1292_CR4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031\u20137.","journal-title":"N Engl J Med"},{"key":"1292_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/ejh.12695","volume":"97","author":"N Thielen","year":"2016","unstructured":"Thielen N, Visser O, Ossenkoppele G, Janssen J. Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012. Eur J Haematol. 2016;97:145\u201354.","journal-title":"Eur J Haematol"},{"key":"1292_CR6","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M H\u00f6glund","year":"2013","unstructured":"H\u00f6glund M, Sandin F, Hellstr\u00f6m K, Bj\u00f6reman M, Bj\u00f6rkholm M, Brune M, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122:1284\u201392.","journal-title":"Blood"},{"key":"1292_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/bjh.17989","volume":"196","author":"CCHM Maas","year":"2022","unstructured":"Maas CCHM, van Klaveren D, Ector GICG, Posthuma EFM, Visser O, Westerweel PE, et al. The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018. Br J Haematol. 2022;196:1219\u201324.","journal-title":"Br J Haematol"},{"key":"1292_CR8","unstructured":"Sprycel | European Medicines Agency (EMA) [Internet]. [cited 2024 Oct 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sprycel."},{"key":"1292_CR9","unstructured":"Tasigna | European Medicines Agency (EMA) [Internet]. [cited 2024 Oct 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tasigna."},{"key":"1292_CR10","unstructured":"Bosulif | European Medicines Agency (EMA) [Internet]. [cited 2024 Oct 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bosulif."},{"key":"1292_CR11","unstructured":"Iclusig | European Medicines Agency (EMA) [Internet]. [cited 2024 Oct 4]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/iclusig."},{"key":"1292_CR12","doi-asserted-by":"publisher","first-page":"6269.","DOI":"10.3390\/cancers13246269","volume":"13","author":"M Daskalakis","year":"2021","unstructured":"Daskalakis M, Feller A, Noetzli J, Bonadies N, Arndt V, Baerlocher GM. Potential to improve therapy of chronic myeloid leukemia (CML), especially for patients with older age: Incidence, mortality, and survival rates of patients with CML in Switzerland from 1995 to 2017. Cancers. 2021;13:6269.","journal-title":"Cancers"},{"key":"1292_CR13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/bjh.17213","volume":"193","author":"L Hjort Jakobsen","year":"2021","unstructured":"Hjort Jakobsen L, Stidsholt Roug A, Kiesbye \u00d8vlisen A, Werenberg Marcher C, Beier Ommen H, Theilgaard-M\u00f6nch K, et al. Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000\u20132016: a Danish population-based study. Br J Haematol. 2021;193:482\u20137.","journal-title":"Br J Haematol"},{"key":"1292_CR14","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TML. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137.","journal-title":"J Clin Oncol"},{"key":"1292_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553\u201361.","journal-title":"J Natl Cancer Inst"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01292-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T17:36:13Z","timestamp":1746639373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01292-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1292"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01292-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the North Denmark Region (record number: F2024-106). Informed consent was not required as register-based studies are excepted from ethical approval in Denmark. All methods were performed in accordance with the relevant guidelines and regulations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}